Abstract
The pro-inflammatory interleukin (IL)-17A serum has been characterized in several systemic autoimmune diseases, but not in antisynthetase syndrome (ASS). Therefore, the present study aims firstly to assess the serum level of the IL-17A in patients with ASS, comparing with healthy individuals, and secondly to analyze prospectively this IL in patients with refractory ASS undergoing rituximab treatment. A cross-sectional, single-center study that included 64 patients with ASS who were age-, gender-, and ethnicity-matched to 64 healthy individuals. Disease status was measured by the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. Secondarily, the patients with refractory disease treated with rituximab were prospectively followed for 12 months. The IL-17A was assessed by the ELISA method. The mean age of the patients was 44.8 ± 11.8 years, with a predominance of female gender and Caucasian. The median serum IL-17A level was higher in ASS patients compared with healthy individuals: 9.7 (9.1-10.4) vs. 7.7 (5.7-9.0) pg/mL, respectively, and P < 0.001. However, the demographical, clinical, and laboratory data indicates that disease status did not correlate with serum levels of the IL-17A in ASS patients....Continue Reading
References
Nov 16, 2001·Rheumatology·F W MillerUNKNOWN International Myositis Outcome Assessment Collaborative Study Group
Jul 2, 2003·Health and Quality of Life Outcomes·Bonnie Bruce, James F Fries
May 9, 2006·Arthritis Research & Therapy·Mónica Vigna-PerezRoberto González-Amaro
Jun 18, 2009·Rheumatology·Marthe SemJan Tore Gran
Jan 12, 2010·Internal Medicine Journal·M DugarP J Roberts-Thomson
Jan 29, 2010·Journal of Clinical Immunology·Xiao Qi ChenMiao Yang
Apr 15, 2010·Arthritis Care & Research·Lisa G RiderJeanne E Hicks
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Meike MitsdoerfferVijay K Kuchroo
Dec 9, 2010·Chest·Geoffrey R ConnorsSonye K Danoff
Jan 15, 2011·Scandinavian Journal of Rheumatology·H ShenW Xiao
Feb 26, 2011·Immunity·Yoichiro IwakuraSusumu Nakae
Mar 15, 2011·Arthritis and Rheumatism·Frank L van de VeerdonkLeo A B Joosten
Feb 22, 2012·Current Rheumatology Reports·Anne Tournadre, Pierre Miossec
Jun 26, 2013·Current Rheumatology Reports·Baptiste Hervier, Olivier Benveniste
Aug 7, 2013·Clinics·Marcela Gran Pina CruellasSamuel Katsuyuki Shinjo
Nov 13, 2013·Revista brasileira de reumatologia·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo
Jan 16, 2014·Autoimmunity Reviews·Michael MahlerMarvin J Fritzler
Apr 8, 2014·Autoimmunity Reviews·Jean-Christophe LegaVincent Cottin
Jul 24, 2014·Neuromuscular Disorders : NMD·Ellen M Moran, Frank L Mastaglia
Nov 8, 2014·Scandinavian Journal of Rheumatology·A NotarnicolaF Iannone
Jun 13, 2015·Archivum Immunologiae Et Therapiae Experimentalis·Jacek TabarkiewiczKrzysztof Giannopoulos
Sep 19, 2015·BMC Musculoskeletal Disorders·Ann M ReedUNKNOWN RIM Study Group
Jan 28, 2016·Clinical and Experimental Immunology·A AlunnoR Gerli
Mar 25, 2017·Rheumatology·Iago Pinal-FernandezSonye K Danoff
Apr 8, 2017·Annals of the Rheumatic Diseases·Lisa G RiderUNKNOWN International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisati
May 4, 2017·The Journal of Rheumatology·Jingli ShiGuochun Wang
Feb 25, 2018·Scandinavian Journal of Immunology·L-W ZhangH Hua
Sep 22, 2018·Current Opinion in Rheumatology·Laure GallayBaptiste Hervier
Jan 19, 2019·Advances in Rheumatology·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo
Jan 24, 2019·Advances in Rheumatology·Fernando Henrique Carlos de SouzaSamuel Katsuyuki Shinjo